Soluble MHC class I complexes for targeted immunotherapy

Anna Schappert, Jonathan P. Schneck, Lauren Suarez, Mathias Oelke, Christian Schütz

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Major histocompatibility complexes (MHC) have been used for more than two decades in clinical and pre-clinical approaches of tumor immunotherapy. They have been proven efficient for detecting anti-tumor-specific T cells when utilized as soluble multimers, immobilized on cells or artificial structures such as artificial antigen-presenting cells (aAPC) and have been shown to generate effective anti-tumor responses. In this review we summarize the use of soluble MHC class I complexes in tumor vaccination studies, highlighting the different strategies and their contradicting results. In summary, we believe that soluble MHC class I molecules represent an exciting tool with great potential to impact the understanding and development of immunotherapeutic approaches on many levels from monitoring to treatment.

Original languageEnglish (US)
Pages (from-to)255-258
Number of pages4
JournalLife Sciences
StatePublished - Sep 15 2018


  • Immunotherapy
  • MHC-class I
  • T cells
  • Tumor
  • Vaccination

ASJC Scopus subject areas

  • General Pharmacology, Toxicology and Pharmaceutics
  • General Biochemistry, Genetics and Molecular Biology


Dive into the research topics of 'Soluble MHC class I complexes for targeted immunotherapy'. Together they form a unique fingerprint.

Cite this